Fibryga’s New FDA Approval: A Triumph For Fibrinogen Care
The FDA has expanded the indication of Octapharma’s Fibryga to include AFD. This makes it the first and only on-demand, virus-inactivated, human plasma-derived fibrinogen concentrate approved for this indication. Fibryga’s FDA approval for AFD introduces a groundbreaking on-demand fibrinogen treatment, revolutionizing care for severe bleeding and fibrinogen deficiencies. To learn more read this blog.